DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast – 2036” report provides comprehensive insights into the Huntington’s Disease market size, historical and forecasted epidemiology, current and emerging treatment landscape, and market opportunity across the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Download DelveInsight’s comprehensive Huntington’s Disease Market Report to explore emerging therapies, key players, and future treatment landscapes: https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Takeaways from the Huntington’s Disease Market Report
- The global Huntington’s Disease Market was valued at approximately USD 320 million in 2025 and is projected to grow at a CAGR of 14%, driven by the anticipated entry of disease-modifying gene and RNA-based therapies through 2036.
- In the United States, the total prevalent cases of Huntington’s Disease stood at approximately 44,000 in 2025, while EU4 and the UK together recorded approximately 37,000 prevalent cases the same year.
- Huntington’s Disease is more prevalent in individuals aged 60 years and above, accounting for approximately 50% of total cases across the 7MM.
- AUSTEDO (Teva Pharmaceuticals) captured the highest revenue among approved therapies, accounting for approximately USD 167 million in 2025.
- In September 2025, Skyhawk Therapeutics announced positive results from the first interim analysis of the Part C patient cohort in its Phase I trial of SKY-0515, showing dose-dependent reductions of mutant huntingtin (mHTT) protein, including a 62% reduction at the 9 mg dose.
- In March 2025, PTC Therapeutics announced that its Phase II PIVOT-HD study of PTC518 (votoplam) met its primary endpoint of reduction in blood Huntingtin protein levels at Week 12, with favorable safety and tolerability.
- In December 2024, Novartis entered into a global license and collaboration agreement with PTC Therapeutics for PTC518, positioning it as a potential first oral disease-modifying therapy for Huntington’s Disease.
- Leading Huntington’s Disease companies developing therapies include Teva Pharmaceuticals, Neurocrine Biosciences, Novartis Pharmaceuticals, Skyhawk Therapeutics, Alnylam Pharmaceuticals, Roche, UniQure Biopharma, and others.
Access DelveInsight’s in-depth Huntington’s Disease Market Analysis for a closer look at promising breakthroughs
Huntington’s Disease Market Report Scope
The Huntington’s Disease Market Report provides an assessment of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM market size from 2022 to 2036. The report also covers treatment algorithms, market practices, unmet needs, and key opportunities shaping the future market landscape.
Huntington’s Disease Overview
Huntington’s Disease is a rare, inherited, progressive brain disorder caused by a mutation in the HTT gene on chromosome 4, resulting in the production of abnormal huntingtin protein and gradual nerve cell damage. It follows an autosomal dominant inheritance pattern, meaning individuals who inherit the faulty gene will develop the disease. Symptoms typically emerge in adulthood and include involuntary movements (chorea), cognitive decline, and psychiatric manifestations such as depression and irritability.
Despite advances in understanding disease pathology, treatment remains largely symptomatic, with no curative or disease-modifying options currently available. Growing focus on genetic and biomarker-driven approaches, including mutant huntingtin (mHTT)-lowering strategies, is shaping the future treatment paradigm and enabling earlier intervention through gene therapies, antisense oligonucleotides, and RNA-based approaches.
Huntington’s Disease Emerging Drugs Profile
SKY-0515 – Skyhawk Therapeutics
SKY-0515 is an orally administered, investigational small molecule RNA modulator developed through Skyhawk’s proprietary SKYSTAR platform. It is designed to therapeutically reduce both HTT protein and PMS1 protein, the latter being an additional key driver of somatic CAG repeat expansion and Huntington’s Disease pathology. The Phase II/III FALCON-HD trial has expanded worldwide, with more than 90 patients treated to date. The program is currently in Phase III development.
Votoplam (PTC518) – Novartis Pharmaceuticals
Votoplam is a small molecule splicing modifier that acts via a unique mechanism to promote inclusion of a novel pseudoexon containing a premature termination codon, triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels. The therapy is licensed to Novartis under a global collaboration with PTC Therapeutics and is currently in Phase III development.
Explore groundbreaking therapies and clinical trials in the Huntington’s Disease Market. Access DelveInsight’s detailed report:
The Huntington’s Disease Market Report Provides Insights Into
- Detailed assessment of companies developing therapies for Huntington’s Disease, along with market size and share estimates by therapy.
- Evaluation of therapeutic candidates across Phase III and Phase I stages of development.
- Analysis of targeted therapeutics, including RNA modulators, splicing modifiers, and VMAT2 inhibitors.
- Assessment of pipeline drugs based on development stage, route of administration, mechanism of action, and molecule type.
- Detailed analysis of collaborations, acquisitions and mergers, licensing agreements, and patent information shaping future market advancement.
- Comprehensive evaluation of marketed and emerging therapies and their potential market uptake.
Huntington’s Disease Companies
Key companies involved in the Huntington’s Disease Market include:
- Teva Pharmaceuticals
- Neurocrine Biosciences
- Novartis Pharmaceuticals
- Skyhawk Therapeutics
- Alnylam Pharmaceuticals
- Roche
- UniQure Biopharma
- Others
Huntington’s Disease Market – Route of Administration
The Huntington’s Disease Market Report provides a therapeutic assessment of pipeline and marketed drugs by route of administration.
- Oral
Huntington’s Disease Market – Molecule Types
Huntington’s Disease products are categorized into the following molecule types:
- Small Molecule (VMAT2 Inhibitor)
- RNA Modulator
- RNA Splicing Modifier
- Antisense Oligonucleotide
Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments: https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=mpr
Scope of the Huntington’s Disease Market Report
- Coverage: 7MM – United States, EU4, United Kingdom, and Japan
- Study Period: 2022–2036
- Forecast Period: 2026–2036
- Huntington’s Disease Companies: Teva Pharmaceuticals, Neurocrine Biosciences, Novartis Pharmaceuticals, Skyhawk Therapeutics, Alnylam Pharmaceuticals, Roche, UniQure Biopharma, and others
- Huntington’s Disease Therapies: AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, ANX005, and others
- Huntington’s Disease Market CAGR: Approximately 14% during 2026–2036
- Therapeutic Assessment by Clinical Stage: Marketed, Phase III, and Phase I
Table of Contents
- Introduction
- Executive Summary
- Huntington’s Disease: Overview
- Epidemiology and Patient Burden Assessment
- Huntington’s Disease Current Treatment Practices
- Huntington’s Disease Marketed Drugs
- Huntington’s Disease Emerging Drugs
- Huntington’s Disease Pipeline Development Activities
- Huntington’s Disease Market Outlook and Drugs Uptake
- Huntington’s Disease Market Access and Reimbursement
- Latest KOL Views on Huntington’s Disease
- Huntington’s Disease Qualitative Analysis
- Huntington’s Disease Market Size and Forecast, 2022–2036
- Huntington’s Disease Key Companies
- Huntington’s Disease Market Drivers and Barriers
- Appendix
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm providing high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and actionable insights to clients worldwide.
Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
